US FDA Extends Approval for GSK's AREXVY RSV Vaccine to Adults in 50-59 Age Group

Friday, 7 June 2024, 20:08

The US FDA has granted expanded approval for GSK's AREXVY vaccine, making it the first RSV vaccine for adults aged 50-59 at higher risk. This significant milestone provides a new preventive option against Respiratory Syncytial Virus for a vulnerable age group, offering crucial protection.

https://store.livarava.com/c2209ed1-2524-11ef-a412-9d5fa15a64d8.jpg — US FDA Extends Approval for GSK's AREXVY RSV Vaccine to Adults in 50-59 Age Group

GSK's AREXVY RSV Vaccine Expansion

The US FDA has granted expanded approval for GSK's AREXVY vaccine for adults aged 50-59, marking a significant development in RSV prevention.

Impact on Public Health

Enhanced Protection: Offering preventive measures for a vulnerable age group.
New Preventive Option: Significant approval for combating RSV infections.

This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.